A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of tapered KWA-0711 dose in chronic constipation patients.

• Phase: Phase 2

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• The patients who experienced fewer than three spontaneous bowel movements per week for more than 6 months prior to the enrollment.

• The patients who experienced one or more of the following signs or symptoms during more than 25% of bowel movements for more than 6 months: straining, lumpy or hard stools, and a sensation of incomplete evacuation

Exclusion Criteria:

• Patients who have secondary constipation caused by systemic disorder.

• Patients who have organic constipation.

• Patients who received intestinal resection.